Hidden muscle loss may signal worsening fatty liver
NCT ID NCT07598916
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will check how often muscle loss (sarcopenia) happens in 120 adults with metabolic fatty liver disease. Researchers will also see if muscle loss is linked to more severe liver scarring. The goal is to better understand the connection, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD) attending the Department of Tropical Medicine \& Gastroenterology at Al-Rajhy Liver Hospital, Assiut University, during the study period.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: The study is intended to include adult patients with metabolic dysfunction-associated steatotic liver disease which will be diagnosed based on imaging study plus one of the following criteria \[8\]: 1. BMI ≥ 25 kg/m2 or waist circumference \> 94 cm in men, \> 80 cm in women 2. Fasting serum glucose ≥ 100 mg/dL (≥ 5.6 mmol/L) or 2-hour post-load glucose level ≥ 140 mg/dL (≥ 7.8 mmol/L) or hemoglobin A1C (HbA1C) ≥ 5.7% or on specific drug treatment 3. Blood pressure ≥ 130/85 mmHg or specific drug treatment 4. Plasma triglycerides ≥ 150 mg/dL (≥ 1.70 mmol/L) or specific drug treatment 5. Plasma high-density lipoprotein (HDL)-cholesterol \< 40 mg/dL (\< 1.0 mmol/L) for men and \< 50 mg/dL (\< 1.3 mmol/L) for women or specific drug treatment For significant steatosis grading, hepatic steatosis index (HSI) will be used (BMI, diabetes mellitus, and aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio; cut-off score: \>36). \[9\]. For significant fibrosis staging, both liver stiffness measurement and several fibrosis scores will be used. Fibrosis scores will include NAFLD fibrosis score (BMI, age, hyperglycemia, AST/ALT ratio, albumin, and platelet count; cut-off score: ≥ 0.675) \[9\]. Exclusion Criteria: 1. Age less than 18 years old or more than 65 years old 2. Pregnant patients 3. Chronic hepatitis C virus and/or hepatitis B virus infection 4. Any alcohol consumption 5. Autoimmune hepatitis 6. Hepatic and/or extrahepatic neoplastic disorders 7. Medication and/or substance use which may lead to hepatic steatosis and/or injury 8. Eating disorders 9. Comorbidities such as neuromuscular, pulmonary, and renal disorders 10. Use of anabolic steroids
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Sarcopenia among patients with metabolic dysfunction-associated steatotic liver disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.